Physician profile
David Leibstein
NPI 1598714321
$6,019.36
in general payments reported to CMS, 2019-2025
25 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $389 · 2021: $459 · 2022: $1,331 · 2023: $1,404 · 2024: $972 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,983.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,380.88 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $555.42 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Johnson & Johnson Vision Care, INC. | $550.22 | 2019-2024 | Acuvue |
| Alcon Vision LLC | $502.79 | 2019-2024 | Total30, Precision 1 |
| Biotissue Holdings INC. | $409.43 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $332.23 | 2023-2025 | Cequa |
| Visioneering Technologies, INC. | $224.20 | 2019-2023 | |
| Sight Sciences, INC. | $212.48 | 2019-2023 | Tearcare System |
| Amgen INC. | $205.80 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $203.23 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $175.45 | 2021-2022 | |
| Lumenis Be INC | $148.52 | 2022 | |
| Ocular Therapeutix, INC. | $133.84 | 2022 | |
| Genzyme Corporation | $133.03 | 2020-2022 | |
| Glaukos Corporation | $126.20 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $119.09 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.95 | 2019 | |
| Harrow Eye, LLC | $81.58 | 2025 | Vevye |
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Kala Pharmaceuticals, INC. | $66.37 | 2021 | |
| Asd Specialty Healthcare, LLC | $62.15 | 2020 | |
| Maculogix, INC. | $58.26 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $54.00 | 2019 | |
| Coopersurgical, INC. | $33.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Leibstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.